-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today (March 23), Huahai Pharmaceutical was accepted by CDE for its imitation of Sitagliptin Phosphate Tablets of Type 4 application.
Sitagliptin is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Merck.
The sales of sitagliptin on the terminal of public medical institutions in China
Source: Mi Nei.
According to Meinenet data, in 2019, China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal sitagliptin sales approached 1 billion yuan; in 2020H1, its sales increased by 15.
Sitagliptin Phosphate Tablets Approval Enterprise Under Review
Source: Meinenet MED2.
At present, the only companies approved for sitagliptin phosphate tablets in the domestic market are Merck and Dongyang Pharmaceutical, and Chia Tai Tianqing Pharmaceutical Group.
Source: Minet database